Claim Listing

1-13. (Canceled)

- 14. (Previously Amended) A method of treating or preventing severe acute respiratory syndrome (SARS) in an individual in need thereof, the method comprising administering an effective amount of IFN-α to the individual.
- 15. (Original) The method of claim 14, wherein the IFN- α is administered within 24 hours of the appearance of a symptom of SARS in the individual.
- 16. (Original) The method of claim 14, wherein the IFN- α is administered within 48 hours of the appearance of a symptom of SARS in the individual.

17-19. (Canceled)

- 20. (Previously Amended) A method of treating or preventing severe acute respiratory syndrome (SARS) in an individual in need thereof, the method comprising administering an effective amount of IFN- α and an effective amount of IFN- γ to the individual.
- 21. (Original) The method of claim 20, wherein the IFN- α and the IFN- γ are administered within 24 hours of the appearance of a symptom of SARS in the individual.
- 22. (Original) The method of claim 20, wherein the IFN- α and the IFN- γ are administered within 48 hours of the appearance of a symptom of SARS in the individual.
- 23. (Original) A method of reducing the risk that an individual will develop severe acute respiratory syndrome (SARS), the method comprising administering to the individual an effective amount of IFN- α .

24. (Canceled)

10/814,701 Docket No. 606319-4502US

25. (Original) A method of reducing the risk that an individual will develop severe acute respiratory syndrome (SARS), the method comprising administering to the individual an effective amount of IFN- α and an effective amount of IFN- γ .

- 26. (Previously Amended) The method of any one of claims 14-16, 20-23 and 25, further comprising administering an effective amount of a nucleotide analog or a nucleoside analog.
- 27. (Previously Amended) The method of any one of claims 14-16, 20-23 and 25, further comprising administering an effective amount of ribavirin.
- 28. (Previously Amended) The method of any one of claims 14-16, 20-23 and 25, wherein the IFN- α is a consensus interferon.